Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Outlook Therapeutics (OTLK) over the last 8 years, with Q4 2025 value amounting to $2.8 million.

  • Outlook Therapeutics' Gains from Investment Securities rose 10693.22% to $2.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $48862.0, marking a year-over-year increase of 10012.11%. This contributed to the annual value of $4.4 million for FY2025, which is 11127.67% up from last year.
  • Outlook Therapeutics' Gains from Investment Securities amounted to $2.8 million in Q4 2025, which was up 10693.22% from -$2.7 million recorded in Q3 2025.
  • Outlook Therapeutics' Gains from Investment Securities' 5-year high stood at $2.8 million during Q4 2025, with a 5-year trough of -$40.3 million in Q4 2024.